These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 9836619)

  • 1. Astressin analogues (corticotropin-releasing factor antagonists) with extended duration of action in the rat.
    Rivier J; Gulyas J; Corrigan A; Martinez V; Craig AG; Taché Y; Vale W; Rivier C
    J Med Chem; 1998 Dec; 41(25):5012-9. PubMed ID: 9836619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Constrained corticotropin-releasing factor (CRF) agonists and antagonists with i-(i+3) Glu-Xaa-DXbb-Lys bridges.
    Koerber SC; Gulyas J; Lahrichi SL; Corrigan A; Craig AG; Rivier C; Vale W; Rivier J
    J Med Chem; 1998 Dec; 41(25):5002-11. PubMed ID: 9836618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal-size, constrained corticotropin-releasing factor agonists with i-(i+3) Glu-Lys and Lys-Glu bridges.
    Rivier J; Lahrichi SL; Gulyas J; Erchegyi J; Koerber SC; Craig AG; Corrigan A; Rivier C; Vale W
    J Med Chem; 1998 Jul; 41(14):2614-20. PubMed ID: 9651165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Constrained corticotropin releasing factor antagonists (astressin analogues) with long duration of action in the rat.
    Rivier JE; Kirby DA; Lahrichi SL; Corrigan A; Vale WW; Rivier CL
    J Med Chem; 1999 Aug; 42(16):3175-82. PubMed ID: 10447963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Constrained corticotropin-releasing factor antagonists with i-(i + 3) Glu-Lys bridges.
    Miranda A; Lahrichi SL; Gulyas J; Koerber SC; Craig AG; Corrigan A; Rivier C; Vale W; Rivier J
    J Med Chem; 1997 Oct; 40(22):3651-8. PubMed ID: 9357532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corticotropin releasing factor (CRF) agonists with reduced amide bonds and Ser7 substitutions.
    Cervini L; Theobald P; Corrigan A; Craig AG; Rivier C; Vale W; Rivier J
    J Med Chem; 1999 Feb; 42(4):761-8. PubMed ID: 10052982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor.
    Gulyas J; Rivier C; Perrin M; Koerber SC; Sutton S; Corrigan A; Lahrichi SL; Craig AG; Vale W; Rivier J
    Proc Natl Acad Sci U S A; 1995 Nov; 92(23):10575-9. PubMed ID: 7479843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conformationally restricted competitive antagonists of human/rat corticotropin-releasing factor.
    Miranda A; Koerber SC; Gulyas J; Lahrichi SL; Craig AG; Corrigan A; Hagler A; Rivier C; Vale W; Rivier J
    J Med Chem; 1994 May; 37(10):1450-9. PubMed ID: 8182703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and relative potencies of new constrained CRF antagonists.
    Hernandez JF; Kornreich W; Rivier C; Miranda A; Yamamoto G; Andrews J; Taché Y; Vale W; Rivier J
    J Med Chem; 1993 Oct; 36(20):2860-7. PubMed ID: 8411001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Central injection of a new corticotropin-releasing factor (CRF) antagonist, astressin, blocks CRF- and stress-related alterations of gastric and colonic motor function.
    Martínez V; Rivier J; Wang L; Taché Y
    J Pharmacol Exp Ther; 1997 Feb; 280(2):754-60. PubMed ID: 9023288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists.
    Rivier J; Gulyas J; Kirby D; Low W; Perrin MH; Kunitake K; DiGruccio M; Vaughan J; Reubi JC; Waser B; Koerber SC; Martinez V; Wang L; Taché Y; Vale W
    J Med Chem; 2002 Oct; 45(21):4737-47. PubMed ID: 12361401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel high-affinity photoactivatable antagonists of corticotropin-releasing factor (CRF) photoaffinity labeling studies on CRF receptor, type 1 (CRFR1).
    Bonk I; Rühmann A
    Eur J Biochem; 2000 May; 267(10):3017-24. PubMed ID: 10806401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human growth hormone-releasing hormone hGHRH(1-29)-NH2: systematic structure-activity relationship studies.
    Cervini LA; Donaldson CJ; Koerber SC; Vale WW; Rivier JE
    J Med Chem; 1998 Feb; 41(5):717-27. PubMed ID: 9513600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral injection of a new corticotropin-releasing factor (CRF) antagonist, astressin, blocks peripheral CRF- and abdominal surgery-induced delayed gastric emptying in rats.
    Martínez V; Rivier J; Taché Y
    J Pharmacol Exp Ther; 1999 Aug; 290(2):629-34. PubMed ID: 10411571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single-point slight alteration set as a tool for structure-activity relationship studies of ovine corticotropin releasing factor.
    Beyermann M; Fechner K; Furkert J; Krause E; Bienert M
    J Med Chem; 1996 Aug; 39(17):3324-30. PubMed ID: 8765516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological activity of N-terminal lipidated and/or fluorescently labeled conjugates of astressin as corticotropin releasing factor antagonists.
    Rijkers DT; den Hartog JA; Liskamp RM
    Bioorg Med Chem; 2004 Oct; 12(19):5099-106. PubMed ID: 15351393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An optimized solid phase synthesis strategy--including on-resin lactamization--of astressin, its retro-, inverso-, and retro-inverso isomers as corticotropin releasing factor antagonists.
    Rijkers DT; den Hartog JA; Liskamp RM
    Biopolymers; 2002 Feb; 63(2):141-9. PubMed ID: 11787002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding differences of human and amphibian corticotropin-releasing factor type 1 (CRF(1)) receptors: identification of amino acids mediating high-affinity astressin binding and functional antagonism.
    Dautzenberg FM; Wille S
    Regul Pept; 2004 May; 118(3):165-73. PubMed ID: 15003833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stressin1-A, a potent corticotropin releasing factor receptor 1 (CRF1)-selective peptide agonist.
    Rivier J; Gulyas J; Kunitake K; DiGruccio M; Cantle JP; Perrin MH; Donaldson C; Vaughan J; Million M; Gourcerol G; Adelson DW; Rivier C; Taché Y; Vale W
    J Med Chem; 2007 Apr; 50(7):1668-74. PubMed ID: 17335188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of pituitary and brain receptors for corticotrophin-releasing factor in modulating alcohol-induced ACTH secretion in the rat.
    Rivier C; Rivier J; Lee S
    Brain Res; 1996 May; 721(1-2):83-90. PubMed ID: 8793087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.